Although molecular analysis has failed to reveal consistently occurring genetic alterations in human prostate cancer, both dominantly acting oncogenic activities as well as loss of growth suppressor functions have been identified. Oncogenic mutations in the c-Ha-ras gene as well as abnormally elevated c-myc mRNA levels have been detected in human prostate cancer. In addition, early studies demonstrating allelic loss and, more recently, mutations in the retinoblastoma and p53 gene indicate that loss of growth suppressor functions are involved in progression. As in other cancers, potentially synergistic relationships between these two general classes of genetic alterations during carcinogenesis have not been established. Experimental approaches which focus on the normal function of proto- oncogenes and growth suppressor genes have thus far failed to provide an understanding of synergistic relationships between these two classes. One approach to this dilemma is to establish an in vivo model system where these activities can be independently manipulated and the resulting phenotypic alterations investigated at the molecular and cellular level. This approach will establish complementation relationships that can be applied to the development of objective molecular markers for prostate cancer in man. We will use a transgenic/mouse prostate reconstitution (TMPR) model system to study the complementation relationships between dominantly acting oncogenes and loss of normal p53 function. Recent studies suggest that loss of normal p53 function is highly selected for during ras+myc-induced carcinogenesis using the reconstitution model. As we have previously documented that ras, myc and ras+myc activities produce unique phenotypic alterations using normal wild type prostate tissues, the impact of a p53- null environment on these phenotypic alterations can be clearly elucidated. Initially the ras and myc oncogenes will be introduced singly or together into total urogenital sinus tissue derived from p53-null mice. This approach will be extended via similar studies which involve gene transfer that is restricted to the mesenchymal or epithelial compartment. We will subsequently use transgenic mouse urogenital sinus tissues containing specific p53 mutations for similar studies. Cell lines derived during these studies will provide useful substrates for evaluating mechanisms involved in loss of p53 function which may be unique to prostate cancer and for testing the biological activities of growth modulators. These studies will result in the classification of complementation relationships between the presence of relevant dominantly acting oncogene activities and loss of growth suppressor function and thus illuminate the clinical significance of these molecular markers in prostate cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
3P50CA058204-03S2
Application #
3731465
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
3
Fiscal Year
1995
Total Cost
Indirect Cost
Name
Baylor College of Medicine
Department
Type
DUNS #
074615394
City
Houston
State
TX
Country
United States
Zip Code
77030
Olar, Adriana; He, Dandan; Florentin, Diego et al. (2014) Biological correlates of prostate cancer perineural invasion diameter. Hum Pathol 45:1365-9
Olar, Adriana; He, Dandan; Florentin, Diego et al. (2014) Biologic correlates and significance of axonogenesis in prostate cancer. Hum Pathol 45:1358-64
Sonpavde, Guru; Wang, Mingjun; Peterson, Leif E et al. (2014) HLA-restricted NY-ESO-1 peptide immunotherapy for metastatic castration resistant prostate cancer. Invest New Drugs 32:235-242
Nakka, Manjula; Agoulnik, Irina U; Weigel, Nancy L (2013) Targeted disruption of the p160 coactivator interface of androgen receptor (AR) selectively inhibits AR activity in both androgen-dependent and castration-resistant AR-expressing prostate cancer cells. Int J Biochem Cell Biol 45:763-72
Ding, Yi; He, Dandan; Florentin, Diego et al. (2013) Semaphorin 4F as a critical regulator of neuroepithelial interactions and a biomarker of aggressive prostate cancer. Clin Cancer Res 19:6101-11
Feng, Shu; Dakhova, Olga; Creighton, Chad J et al. (2013) Endocrine fibroblast growth factor FGF19 promotes prostate cancer progression. Cancer Res 73:2551-62
Yang, Feng; Zhang, Yongyou; Ressler, Steven J et al. (2013) FGFR1 is essential for prostate cancer progression and metastasis. Cancer Res 73:3716-24
Yang, Guang; Goltsov, Alexei A; Ren, Chengzhen et al. (2012) Caveolin-1 upregulation contributes to c-Myc-induced high-grade prostatic intraepithelial neoplasia and prostate cancer. Mol Cancer Res 10:218-29
Sonpavde, Guru; Thompson, Timothy C; Jain, Rajul K et al. (2011) GLIPR1 tumor suppressor gene expressed by adenoviral vector as neoadjuvant intraprostatic injection for localized intermediate or high-risk prostate cancer preceding radical prostatectomy. Clin Cancer Res 17:7174-82
Wang, Jianghua; Cai, Yi; Shao, Long-Jiang et al. (2011) Activation of NF-{kappa}B by TMPRSS2/ERG Fusion Isoforms through Toll-Like Receptor-4. Cancer Res 71:1325-33

Showing the most recent 10 out of 262 publications